$12.81
6.15%
Nasdaq, Fri, Nov 01 2024
ISIN
US2537482067
Symbol
DFFN
Sector
Industry

Diffusion Pharmaceuticals Inc. Target price 2024 - Analyst rating & recommendation

Diffusion Pharmaceuticals Inc. Classifications & Recommendation:

Buy
100%

Diffusion Pharmaceuticals Inc. Price Target

Target Price $57.60
Price $12.81
Potential
Number of Estimates 5
5 Analysts have issued a price target Diffusion Pharmaceuticals Inc. 2025 . The average Diffusion Pharmaceuticals Inc. target price is $57.60. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend Diffusion Pharmaceuticals Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Diffusion Pharmaceuticals Inc. stock has an average upside potential 2025 of . Most analysts recommend the Diffusion Pharmaceuticals Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 7.14 8.66
21.29%
EBITDA Margin -109.38% -173.44%
58.56%
Net Margin -94.75% -151.00%
59.37%

5 Analysts have issued a sales forecast Diffusion Pharmaceuticals Inc. 2024 . The average Diffusion Pharmaceuticals Inc. sales estimate is

$8.7m
Unlock
. This is
10.26% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$12.4m 28.50%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $7.1m
2024
$8.7m 21.29%
Unlock
2025
$3.2m 63.05%
Unlock
2026
$0.0 100.00%
Unlock

2 Analysts have issued an Diffusion Pharmaceuticals Inc. EBITDA forecast 2024. The average Diffusion Pharmaceuticals Inc. EBITDA estimate is

$-15.0m
Unlock
. This is
39.72% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-13.8m 28.37%
Unlock
, the lowest is
$-16.2m 51.07%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-7.8m 51.10%
2024
$-15.0m 92.32%
Unlock
2025
$-35.9m 138.84%
Unlock
2026
$-61.8m 72.16%
Unlock
2027
$-59.0m 4.47%
Unlock
2028
$-216m 266.44%
Unlock

EBITDA Margin

2023 -109.38%
2024
-173.44% 58.56%
Unlock
2025
-1,121.05% 546.36%
Unlock

2 Diffusion Pharmaceuticals Inc. Analysts have issued a net profit forecast 2024. The average Diffusion Pharmaceuticals Inc. net profit estimate is

$-13.1m
Unlock
. This is
11.43% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-13.0m 11.70%
Unlock
, the lowest is
$-13.1m 11.16%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-6.8m 92.85%
2024
$-13.1m 93.35%
Unlock
2025
$-22.4m 71.25%
Unlock
2026
$-29.5m 31.65%
Unlock
2027
$-28.6m 3.05%
Unlock
2028
$-96.4m 237.32%
Unlock

Net Margin

2023 -94.75%
2024
-151.00% 59.37%
Unlock
2025
-699.96% 363.55%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.82 -1.59
92.85% 93.90%
P/E negative
EV/Sales 7.00

2 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast for earnings per share. The average Diffusion Pharmaceuticals Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.59
Unlock
. This is
11.17% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.58 11.73%
Unlock
, the lowest is
$-1.59 11.17%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.82 92.85%
2024
$-1.59 93.90%
Unlock
2025
$-2.72 71.07%
Unlock
2026
$-3.58 31.62%
Unlock
2027
$-3.47 3.07%
Unlock
2028
$-11.69 236.89%
Unlock

P/E ratio

Current -7.17 714.77%
2024
-8.08 12.69%
Unlock
2025
-4.72 41.58%
Unlock
2026
-3.58 24.15%
Unlock
2027
-3.70 3.35%
Unlock
2028
-1.10 70.27%
Unlock

Based on analysts' sales estimates for 2024, the Diffusion Pharmaceuticals Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
12.21
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.28
2024
7.00 11.50%
Unlock
2025
18.95 170.63%
Unlock

P/S ratio

Current
2024
12.21 11.43%
Unlock
2025
33.04 170.62%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today